BACKGROUND: About 20% of patients with prostate cancer have an ECOG performance status (PS) X2 at diagnosis. We investigate if current treatment options for castration-resistant prostate cancer (CRPC) may decrease the risk of death even in patients with ECOG PS of 2. METHODS: PubMed was reviewed for phase III randomized trials in patients with CRPC progressed after docetaxel chemotherapy. Characteristics of each study and the relative hazard ratio (HR) for overall survival and 95% confidence interval (CI) were collected. Summary HR was calculated using random-or fixed-effects models depending on the heterogeneity of included studies. RESULTS: A total of 3,149 patients was available for meta-analysis. In the overall population, the experimental treatments decrease the risk of death by 31% (HR ¼ 0.69; 95% CI: 0.63-0.76; Po0.001). The activity of experimental treatments was similar in 2,859 patients with ECOG-PS ¼ 0 or 1 with a reduced risk of death of 31% (HR ¼ 0.69; 95% CI: 0.62-0.76). A total of 290 patients (9.2%) had ECOG-PS ¼ 2 and experimental treatments decreased the risk of death by 26% (HR ¼ 0.74; 95% CI: 0.56-0.98; P ¼ 0.035) compared with the controls even in this sub-group. When patients were stratified by type of treatment, the reduction of the risk of death was confirmed for hormonal therapies: abiraterone and enzalutamide (HR ¼ 0.72; 95% CI: 0.52-0.99; P ¼ 0.046), but not for chemotherapy (HR ¼ 0.81; 95% CI: 0.48-1.37; P ¼ 0.43). CONCLUSIONS: We believe this is the first study reporting a benefit in second-line setting for CRPC patients previously treated with docetaxel and poor PS.
INTRODUCTION
Prostate cancer is the most frequent cause of cancer in male; in 2012, about 241 740 new cases and 28 170 deaths have been estimated in the USA. 1 Androgen-deprivation therapy with the luteinizing hormone-releasing analogue is the gold standard for advanced disease but despite the initial response, patients will develop progressive castration-resistant prostate cancer (CRPC).
Treatment of CRPC has completely changed in 2004 with the approval of docetaxel based on improvement of survival and control of disease compared with mitoxantrone (Mito). 2, 3 In recent years, several agents have reported to increase survival, delay disease progression and improve quality of life after docetaxel progression. 4 About 20% of patients with a new diagnosis of prostate cancer have an ECOG performance status (PS) X2, and the portion is probably higher in patients with advanced disease. 5 Furthermore, PS and other factors such as baseline value of hemoglobin under the lower normal limit, weight loss and pain have been related to a short survival in patients with hormone sensitive and CRPC. [6] [7] [8] Despite these data, patients with poor PS enrolled in major clinical trials are less than 10%, and no evidence are currently available to the benefit of treating this subgroup. Therefore, we sought to investigate whether current available treatments for CRPC progressed after first-line docetaxel-based chemotherapy (CHT) may decrease the risk of death even in patients with poor PS.
MATERIALS AND METHODS

Definition of the outcome
For each trial, the experimental treatment was compared with the control one. Overall survival (OS) was evaluated in the experimental arms over the control arms in the entire cohort, and in the patients with poor PS based on the hazard ratio (HR), and relative 95% confidence interval (CI) was reported in the study results. Patients with poor PS were defined based on ECOG scale and have the PS ¼ 2. 9 Selection of the studies We reviewed PubMed for citations from January 2005 to December 2012. The search criteria were limited to articles published in English language and phase III clinical trials. The entry term for the search was 'CRPC.' The search was restricted to randomized controlled trials in which the experimental treatment was compared with the control one in CRPC patients. If more than one publication was found for the same trial, the most recent was considered for analysis. Other characteristics required for article inclusion were a previous treatment with docetaxel and the 1 inclusion of patients with PS equal to two other than the availability of data for OS.
Study quality was assessed by using the Jadad 7-item scale that included the randomization, double-blinding and withdrawals; the score was reported between 0 and 5. 10 
Data extraction
Data extraction was conducted independently by RI and AA according to the preferred reporting items for systematic review and meta-analysis statement, 11 and any type of discrepancies was resolved by consensus. Data extracted for each trial were: first author's name, years of publication, trial phase, the number of patients evaluable, the number of patients with PS-2, the number of arms, randomization rate, drugs used in the experimental and in the control arm, dosage, median age, percentage of bone metastases, median follow-up, median treatment duration, median progression-free survival and median OS with the relative HR and 95% CI, in overall, PS-0/1 and PS-2 population.
Statistical method
For the calculation of the incidence of patients with PS ¼ 0-1 and PS ¼ 2, the number of patients in each group and the total number of patients enrolled in the study were extracted from the baseline characteristic of patients of the selected trials.
The HRs and the relative 95% CI for OS in the entire cohort, PS ¼ 0-1 and in PS ¼ 2 patients were extracted from each study. To calculate the 95% CIs, the variance of a log-transformed study-specific HR was derived using the delta method. 12 Statistical heterogeneity between trials included in the meta-analysis was assessed using Cochrane's Q statistic, and inconsistency was quantified with
. 13 The assumption of homogeneity was considered invalid for P-values less than 0.1. Summary HR was calculated using random-or fixed-effects models depending on the heterogeneity of included studies. When substantial heterogeneity was not observed, the pooled estimate calculated based on the fixed-effects model was reported using the inverse variance method.
When substantial heterogeneity was observed, the pooled estimate calculated based on the random-effects model was reported using the Der Simonian et al.
14 method, which considers both within-and betweenstudy variations. Publication bias was evaluated using to funnel plots (plots of study results against precision) and with the Begg et al. 15 and Egger et al. 16 tests. A two-tailed p-value of less than 0.05 was considered statistically significant. All data were collected using Microsoft Office Excel 2007; statistical analyses were performed using PASW statistic software (version 18) and RevMan software for meta-analysis (v. 5.2.3). 17 
RESULTS
The electronic search revealed 18 citations, after screening 13 articles were eliminated because six were sub-analysis of previously published phase III trials, reviews or letters to the editor. A total of five articles was eliminated because of patients Figure 1 . Selection of randomized controlled trials (RCTs) included in the meta-analysis. CRPC, castration-resistant prostate cancer; PS, performance status. were treated in first line of therapy, or they did not receive docetaxel first; one trial was not in CRPC patients and another because designed for patients without CRPC and PSA rising only. Another study (SPARC trial) valuable for the review process was discarded because of not sufficient parameters were available for the meta-analysis process. 18 A total of five full-text articles was reviewed for further assessment; among these, two were excluded because one was updated and one did not enroll PS-2 patients.
At the end of the reviewed process, only three articles were included in the meta-analysis because of their adequate quality and availability of data ( Figure 1) . [19] [20] [21] All were randomized phase III double blind trials: the experimental treatments were abiraterone acetate (ABI), cabazitaxel (CBZ) and enzalutamide (ENZ) while the control arms were placebo for two trials and Mito in the other. Continuously doses of prednisone were used in both arms in two studies. 19, 20 The characteristics of each study are presented in Table 1 .
Overall population A total of 3,149 patients was available for meta-analysis. A total of 1975 patients were treated in the experimental arms with: abiraterone 1000 mg per day p.o. continuously (797 patients), CBZ 25 mg m À 2 by IV injection every 3 weeks (378 patients) or ENZ 160 mg per day p.o. continuously (800 patients). A total of the 1174 patients received the control treatments with Mito 12 mg m À 2 every 3 weeks (377 patients) or with placebo (797 patients).
In the overall population, each experimental treatment decreased the risk of death by 26 to 37% compared with the control arm and the cumulative reduction of the risk of death was 31% (HR ¼ 0.69; 95% CI: 0.63-0.76; Po0.001) ( Table 2) None of the included studies showed a significant reduction of the risk of death in patients with PS-2, while in the overall PS-2 population patients in the experimental arms had a significant reduction of the risk of death by 26% (HR ¼ 0.74; 95% CI: 0.56-0.98; P ¼ 0.035) compared with controls (Table 2) . No significant heterogeneity was found (Q ¼ 0.4, P ¼ 0.82; I 2 ¼ 0.0%) (Figure 2c ). The sub-group analysis based on the type of treatment reported a reduction of the risk of death by hormonal therapies (HT; abiraterone or ENZ) (HR ¼ 0.72; 95% CI: 0.52-0.99; P ¼ 0.046) but not by CHT (CBZ) (HR ¼ 0.81; 95% CI: 0.48-1.37; P ¼ 0.43); no significant heterogeneity was found in both cases, and no differences were found between the two groups ( Figure 3 ).
Study quality
Randomized treatment allocation was generated in all trials. The control arm was the placebo for two trials 20, 21 and Mito in the other. 19 Continuously doses of prednisone were used in both arms in two studies. 19, 20 Follow-up time was reported in all trials ranging from 12.8 to 20.2 months. Jadad' scores for each trial are listed in Table 1 . The mean score was 4.0, and all were high-quality trial (Jadad score 3-5).
Publication bias No significant publication biases were detected: P-values from Begg's and Egger's test were 0.12 and 0.36 for the overall population, 0.12 and 0.30 for PS ¼ 0-1 and 0.60 and 0.89 for PS ¼ 2, respectively.
DISCUSSION
To the best of our knowledge, this is the first meta-analysis to demonstrate a significant reduction of the risk of death by treating patients with CRPC and PS-2. We confirm that these patients represent o10% of entire population enrolled in phase III trials and probably this low number is the major cause for the lack of evidence of treatment activity until now.
We report that current available treatments for post docetaxel treatment of CRPC decrease the risk of death by 31% in the overall population, and the activity of experimental treatment may be related to PS even if the difference in the risk of death between patients PS-0 or 1, and these with PS-2 were only 5% (HR: 0.69 for PS-0 or 1 and 0.74 for PS-2). These results may improve clinical practice, encouraging the treatment of patients with PS-2 at the end of docetaxel therapy even if the expected benefit from treatment needs to be balanced with possible adverse events due to therapy.
Similarly, recent studies in non-small lung cancer reported as the combination regimens of CHTwas better in terms of survival and response rate than a single agent even in patients with PS-2 and without a substantial increase in toxicity. 22, 23 Moreover, a retrospective analysis showed also as these results are transposable in clinical practice. 24 All together, this evidence sustained the idea that patients with PS-2 should be treated with standard therapy if not general contraindications are present.
About prostate cancer, current guidelines do not report the best sequence of therapy after docetaxel failure, and several algorithms have been proposed in medical literature. 4, 25 In registration trials, the incidence of high-grade adverse events was quite similar in the three drugs (55% for abiraterone, 57% for CBZ and 45% for ENZ), [19] [20] [21] but with a different toxicity profile for each one. In fact, CBZ is mainly characterized by hematologic toxicity (neutropenia G3-4 in 82% and anemia G3-4 in 11% of cases) and ABI by cardiovascular toxicity (5% of patients for grade 3 or 4). 19, 20 A patient-based approach may be based on the different toxicity profiles of these drugs, residual toxicity to the docetaxel therapy and patient's comorbidity.
In our study, we found that available hormonal treatments (abiraterone and ENZ) for CRPC decrease the risk of death by 28% compared with controls suggesting a possible role in patients ineligible for second-line chemotherapy, but no evidence is available about patients ineligible for first-line docetaxel.
Recently, a large phase III trial confirmed the activity and safety of ABI in CRPC patients untreated with docetaxel. 4 This study (COU-AA-302) reports as CHT naïve CRPC patients have a similar benefit from ABI compared with post-CHT one in terms of radiographic progression-free survival (HRs: 0.67 vs 0.69, respectively) and control of disease (16.5 vs 5.6 months), but no patients with PS-2 were enrolled. 26, 27 Our data may suggest such as the increased survival found in PS-0/1 patients may be also reached in poor PS patients even in pre-docetaxel setting, considering that recent analysis reported as ABI and ENZ are able to reduce pain, fatigue and skeletal related events in CRPC patients. 21, 28, 29 The results of our meta-analysis may represent an important evidence that available therapies for CRPC are active in patients both with good and poor PS. The quality of this evidence is based on the high rate of Jadad' score for included studies. Nevertheless, some limitations may affect the results of our study. First, this is a meta-analysis based on studies and not on patients' data, therefore confounding variables as patient's comorbidities, extension of disease and differences in other possible prognostic factors could not be incorporated into the analysis. Second, all the included studies were conducted in patients with adequate organ function and no severe comorbidity at study entry, so data about the treatments' activity might be not directly related to overall population with PS-2 and affected by CRPC in clinical practice. Furthermore, PS evaluation is strictly related to the physician's sensitivity and experience. Third, considering the number of patients included with PS-2, the power of this analysis may be low even if it shows a significant difference. It is also important to remark that no definitive conclusions may be performed about the best treatment between hormonal or chemotherapeutic agents for these patients. Fourth, the control arm was the placebo in two studies and Mito in the third one, but this heterogeneity may be mitigated considering that prospective studies on Mito did not show to prolong OS over prednisone. 30, 31 In conclusion, patients affected by CRPC previously treated with docetaxel and poor PS benefit from current available therapies in this setting. The different toxicity profiles of these molecules should be taken into account in the choice of treatment, according to patients' comorbidity and drug availability, even if we found a significant benefit for patients treated with hormonal therapies but not for chemotherapy. Finally, considering the activity of new molecules in good PS patients, we sustain that well-designed trials may elucidate the best strategy for these patients.
